Protagonist Therapeutics (PTGX) Projected to Post Earnings on WednesdayMarket Beat·3 hours agoPTGX-1.34%
Defensive Signals Emerge: Portfolio Rebalancing Ahead of Late-2026 CatalystsGlobal Report·7 hours agoOWL-3.11%MDLZ+4.55%
Allspring Global Investments Holdings LLC Increases Stock Position in Protagonist Therapeutics, Inc. $PTGXMarket Beat·Jul 25 at 02:06 AMPTGX-1.34%
Knott David M Jr Trims Stock Holdings in Protagonist Therapeutics, Inc. $PTGXMarket Beat·Jul 24 at 05:10 AMPTGX-1.34%
Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate OpenSimplywall·Jul 19 at 08:10 AMPTGX-1.34%
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)Tip Ranks·Jul 16 at 09:05 AMPTGX-1.34%RANK-2.17%
Will Icotyde’s Launch and Rusfertide’s Priority Review Change Protagonist Therapeutics’ (PTGX) NarrativeSimplywall·Jul 9 at 10:57 PMPTGX-1.34%
Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts InterestSimplywall·Jul 8 at 06:56 PMPTGX-1.34%
Why Wall Street’s Wrong for Loving Protagonist Therapeutics StockBarchart Option·Jul 2 at 09:21 AMPTGX-1.34%
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Rusfertide Review Optimism And New Hires – Learn WhySimplywall·Jul 1 at 11:07 PMPTGX-1.34%
Protagonist Therapeutics grants inducement awards for 8,650 share options, 2,275 RSUs to new hiresPUBT·Jul 1 at 03:05 PMPTGX-1.34%
Medicare Coverage Could Put These Obesity Drug Stocks In FocusSimplywall·Jun 30 at 10:58 AMMDGL-0.36%PTGX-1.34%
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High - Should You Buy?Market Beat·Jun 29 at 10:00 AMPTGX-1.34%
Protagonist Therapeutics (NASDAQ:PTGX) Lowered to "Buy" Rating by Wall Street ZenMarket Beat·Jun 27 at 12:30 AMPTGX-1.34%
Protagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 SharesMarket Beat·Jun 26 at 04:52 AMPTGX-1.34%
